Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats

Neuroscience

Volumn 156, Issue 4, 2008, Pages 1005-1016

  Terry Jr , A V ^a   Warner, S E ^a   Vandenhuerk, L ^a   Pillai, A ^a   Mahadik, S P ^a   Zhang, G ^b   Bartlett, M G ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

antipsychotic; cognition; neuroleptic; radial arm maze; schizophrenia; water maze

Indexed keywords

CHLORPROMAZINE; OLANZAPINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG STABILITY; LEARNING; LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; TANDEM MASS SPECTROMETRY; WORKING MEMORY;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CHLORPROMAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXPLORATORY BEHAVIOR; HAND STRENGTH; MALE; MAZE LEARNING; MEMORY, SHORT-TERM; MOTOR ACTIVITY; RATS; RATS, WISTAR; REACTION TIME; SPACE PERCEPTION;

EID: 54049128414     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.08.030     Document Type: Article

References (48)

1. Baldessarini R.J., Cohen B.M., and Teicher M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45 (1988) 79-91
2. Barth V.N., Chernet E., Martin L.J., Need A.B., Rash K.S., Morin M., and Phebus L.A. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci 78 (2006) 3007-3012
3. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163 (2000) 495-529
4. Bolden C., Cusack B., and Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 260 (1992) 576-580
5. Bymaster F.P., Felder C.C., Tzavara E., Nomikos G.G., Calligaro D.O., and Mckinzie D.L. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1125-1143
6. Cairo T.A., Woodward T.S., and Ngan E.T. Decreased encoding efficiency in schizophrenia. Biol Psychiatry 59 (2006) 740-746
7. Chetty M., Pillay V.L., Moodley S.V., and Miller R. Response in chronic schizophrenia correlated with chlorpromazine, 7-OH-chlorpromazine and chlorpromazine sulfoxide levels. Eur Neuropsychopharmacol 6 (1996) 85-91
8. Curry S.H., Marshall J.H., Davis J.M., and Janowsky D.S. Chlorpromazine plasma levels and effects. Arch Gen Psychiatry 22 (1970) 289-296
9. Decker M.W., and McGaugh J.L. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7 (1991) 151-168
10. Didriksen M., Kreilgaard M., and Arnt J. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol 542 (2006) 108-115
11. Gardner D.M., Baldessarini R.J., and Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 172 (2005) 1703-1711
12. Gex-Fabry M., Balant-Gorgia A.E., and Balant L.P. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 25 (2003) 46-53
13. Green M.F., Kern R.S., Braff D.L., and Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr Bull 26 (2000) 119-136
14. Green M.F. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. Am J Psychiatry 164 (2007) 992-994
15. Gur R.C., Moelter S.T., and Ragland J.D. Learning and memory in schizophrenia. In: Sharma T., and Harvey P. (Eds). Cognition in schizophrenia: Impairments, importance, and treatment strategies (2000), Oxford University Press, Oxford, UK 73-91
16. Harvey P.D., Green M.F., Keefe R.S., and Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 65 (2004) 361-672
17. Hernandez C.M., Høifødt H., and Terry Jr. A. Spontaneously hypertensive rats: Further evaluation of age-related memory performance and cholinergic marker expression. J Psychiatry Neurosci 28 (2003) 197-209
18. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305 (2003) 625-631
19. Keefe R.S., Roitman S.E., Harvey P.D., Blum C.S., DuPre R.L., Prieto D.M., Davidson M., and Davis K.L. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res 17 1 (1995) 25-33
20. Levin E.D., Galen D.M., and Ellison G.D. Chronic haloperidol effects on oral movements and radial-arm maze performance in rats. Pharmacol Biochem Behav 26 (1987) 1-6
21. Levin E.D. Chronic haloperidol administration does not block acute nicotine-induced improvements in radial-arm maze performance in the rat. Pharmacol Biochem Behav 58 (1997) 899-902
22. McDonald R.J., and White N.M. Hippocampal and nonhippocampal contributions to place learning in rats. Behav Neurosci 109 (1995) 579-593
23. McNamara R.K., and Skelton R.W. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Rev 18 (1993) 33-49
24. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10 (2005) 79-104
25. Nowakowska E., Chodera A., Kus K., and Rybakowski J. Some behavioural effects of risperidone in rats: comparison with haloperidol. Eur Neuropsychopharmacol 9 (1999) 421-426
26. Olton D.S., and Papas B.C. Spatial memory and hippocampal function. Neuropsychologia 17 6 (1979) 669-682
27. Park S., Puschel J., Sauter B.H., Rentsch M., and Hell D. Spatial working memory deficits and clinical symptoms in schizophrenia: a 4-month follow-up study. Biol Psychiatry 46 3 (1999) 392-400
28. Perry P.J., Lund B.C., Sanger T., and Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 21 (2001) 14-20
29. Rao M.L., Hiemke C., Grasmäder K., Baumann P., and TDM Arbeitsgruppe Der AGNP. Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring. Fortschr Neurol Psychiatr 69 (2001) 510-517
30. Rosengarten H., and Quartermain D. The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in 3- and eighteen-month-old rats. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 1047-1054
31. Seeman P., and Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3 (1998) 123-134
32. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124 (1996) 57-73
33. Sergi M.J., Kern R.S., Mintz J., and Green M.F. Learning potential and the prediction of work skill acquisition in schizophrenia. Schizophr Bull 31 (2005) 67-72
34. Terry Jr. A.V., Hernandez C.M., and Buccafusco. Dahl-salt sensitive and salt-resistant rats: examination of learning and memory performance, blood pressure, and the expression of central nicotinic-acetylcholine receptors. Neuroscience 103 (2001) 351-363
35. Terry Jr. A.V., Hill W.D., Parikh V., Evans D.R., Waller J.L., and Mahadik S.P. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology (Berl) 164 (2002) 360-368
36. Terry Jr. A.V., Hill W.D., Parikh V., Waller J.L., Evans D.R., and Mahadik S.P. Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats. Neuropsychopharmacology 28 (2003) 300-309
37. Terry Jr. A.V., Gearhart D.A., Mahadik S.P., Warsi S., Davis L.W., and Waller J.L. Chronic exposure to typical or atypical antipsychotics in rodents: Temporal effects on central alpha 7 nicotinic acetylcholine receptors. Neuroscience 136 (2005) 519-529
38. Terry Jr. A.V., Buccafusco J.J., and Bartoszyk G.D. Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. Psychopharmacology (Berl) 179 (2005) 725-732
39. Terry Jr. A.V., Parikh V., Gearhart D.A., Pillai A., Hohanadel E., Warner S., Nasrallah H.A., and Mahadik S.P. Time dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats. J Pharmacol Exp Ther 318 (2006) 709-724
40. Terry Jr. A.V., Gearhart D.A., Warner S.E., Zhang G., Bartlett M.G., Middlemore M.L., Beck Jr. W.D., Mahadik S.P., and Waller J.L. Oral haloperidol or risperidone treatment in rats: Temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance. Neuroscience 146 (2007) 1316-1332
41. Terry Jr. A.V., Gearhart D.A., Warner S.E., Hohnadel E.J., Middlemore M.L., Zhang G., Bartlett M.G., and Mahadik S.P. Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats. Neuroscience 150 (2007) 413-424
42. Terry Jr. A.V., and Mahadik S.P. Time dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. J Pharmacol Exp Ther 320 (2007) 961-968
43. Treit D., and Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 31 (1988) 959-962
44. Varty G.B., Bakshi V.P., and Geyer M.A. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20 (1999) 311-321
45. Von Huben S.N., Davis S.A., Lay C.C., Katner S.N., Crean R.D., and Taffe M.A. Differential contributions of dopaminergic D1- and D2-like receptors to cognitive function in rhesus monkeys. Psychopharmacology (Berl) 188 (2006) 586-596
46. Winstanley C.A., Chudasama Y., Dalley J.W., Theobald D.E., Glennon J.C., and Robbins T.W. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology (Berl) 167 (2003) 304-314
47. Zhang G., Terry A.V., and Bartlett M.G. Liquid chromatography/tandem mass spectrometry for the simultaneous determination of olanzipine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma. Rapid Commun Mass Spectrom 21 (2007) 920-928
48. Zhang G., Terry A.V., and Bartlett M.G. Sensitive liquid chromatography/tandem mass spectrometry method for the determination of the lipophilic antipsychotic drug chlorpromazine in rat plasma and brain tissue. J Chromatogr B 854 (2007) 68-76